太平洋给予荣泰健康买入评级：2025H1内销双位数增长，智能健康新领域多点开花

Group 1 - The core viewpoint of the report is that Rongtai Health (603579.SH) is given a "buy" rating due to strong performance indicators and growth potential [1] - Domestic online sales are expected to grow by over 30% year-on-year in the first half of 2025, with excellent performance in emerging overseas markets and cross-border e-commerce [1] - Gross margin improved in Q2 2025, supported by increased R&D investment and operational efficiency [1] - The company is diversifying its smart health business, leveraging technology for accelerated growth [1]